Ptc Therapeutics (PTCT) Free Cash Flow Growth (3y) (2015 - 2026)
Powered by 
Analysis
Ptc Therapeutics (PTCT) Free Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -4.45% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 8.92% |
| 10 | Ptc Therapeutics | 5.79 Bn | 3.56 Bn | 340.60 Mn | 101.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 101.92% |
| Mar 31, 2026 | -14.85% |
| Dec 31, 2025 | 40.57% |
| Sep 30, 2025 | -17.15% |
| Jun 30, 2025 | 2.33% |
| Mar 31, 2025 | 116.42% |
| Dec 31, 2024 | 24.21% |
| Sep 30, 2024 | -10.77% |
| Jun 30, 2024 | -17.88% |
| Mar 31, 2024 | 37.12% |
| Dec 31, 2023 | -14.39% |
| Sep 30, 2023 | -42.51% |
| Jun 30, 2023 | 35.80% |
| Mar 31, 2023 | 23.14% |
| Dec 31, 2022 | -127.34% |
| Sep 30, 2022 | -30.03% |
| Jun 30, 2022 | -25.29% |
| Mar 31, 2022 | -33.08% |
| Dec 31, 2021 | -61.73% |
| Sep 30, 2021 | -345.27% |